Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation.

Elagib KE, Goldfarb AN.

Cancer Lett. 2007 Jun 28;251(2):179-86. Epub 2006 Nov 27. Review.

2.

[Advances on pathogenesis research of acute myeloid leukemia with t(8;21)-- review].

Zeng HM, Guo Y, Zhu XF.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Dec;18(6):1632-7. Review. Chinese.

PMID:
21176386
3.

Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation.

de Guzman CG, Warren AJ, Zhang Z, Gartland L, Erickson P, Drabkin H, Hiebert SW, Klug CA.

Mol Cell Biol. 2002 Aug;22(15):5506-17.

4.

The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.

Mandoli A, Singh AA, Prange KHM, Tijchon E, Oerlemans M, Dirks R, Ter Huurne M, Wierenga ATJ, Janssen-Megens EM, Berentsen K, Sharifi N, Kim B, Matarese F, Nguyen LN, Hubner NC, Rao NA, van den Akker E, Altucci L, Vellenga E, Stunnenberg HG, Martens JHA.

Cell Rep. 2016 Nov 15;17(8):2087-2100. doi: 10.1016/j.celrep.2016.08.082.

5.
6.

A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO.

Osman D, Gobert V, Ponthan F, Heidenreich O, Haenlin M, Waltzer L.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12043-8. doi: 10.1073/pnas.0902449106. Epub 2009 Jul 6.

7.

E protein silencing by the leukemogenic AML1-ETO fusion protein.

Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG.

Science. 2004 Aug 27;305(5688):1286-9.

8.

Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice.

Kagiyama Y, Kitaura J, Togami K, Uchida T, Inoue D, Matsukawa T, Izawa K, Kawabata KC, Komeno Y, Oki T, Nakahara F, Sato K, Aburatani H, Kitamura T.

Int J Hematol. 2012 Nov;96(5):638-48. doi: 10.1007/s12185-012-1207-6. Epub 2012 Oct 25.

PMID:
23097187
9.

AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1.

Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S, Hoshida Y, Nakazawa T, Harada Y, Tatsumi N, Tsuboi A, Kawakami M, Oka Y, Oji Y, Aozasa K, Kawase I, Sugiyama H.

Blood. 2006 Apr 15;107(8):3303-12. Epub 2005 Dec 27.

10.
11.

AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.

Jin W, Wu K, Li YZ, Yang WT, Zou B, Zhang F, Zhang J, Wang KK.

Oncogene. 2013 Apr 11;32(15):1978-87. doi: 10.1038/onc.2012.204. Epub 2012 May 28.

PMID:
22641217
12.

Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia.

Fazi F, Zardo G, Gelmetti V, Travaglini L, Ciolfi A, Di Croce L, Rosa A, Bozzoni I, Grignani F, Lo-Coco F, Pelicci PG, Nervi C.

Blood. 2007 May 15;109(10):4432-40. Epub 2007 Jan 23.

13.

The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.

Bakshi R, Zaidi SK, Pande S, Hassan MQ, Young DW, Montecino M, Lian JB, van Wijnen AJ, Stein JL, Stein GS.

J Cell Sci. 2008 Dec 1;121(Pt 23):3981-90. doi: 10.1242/jcs.033431. Epub 2008 Nov 11.

14.

AML-1-ETO-Mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein.

Choi Y, Elagib KE, Goldfarb AN.

Crit Rev Eukaryot Gene Expr. 2005;15(3):207-16. Review.

PMID:
16390317
15.

The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.

Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W, Behre G.

Blood. 2003 Jan 1;101(1):270-7. Epub 2002 Aug 29.

16.

Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.

DeKelver RC, Yan M, Ahn EY, Shia WJ, Speck NA, Zhang DE.

Blood. 2013 May 2;121(18):3714-7. doi: 10.1182/blood-2012-11-465641. Epub 2013 Feb 20.

17.

KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia.

Zhao S, Zhang Y, Sha K, Tang Q, Yang X, Yu C, Liu Z, Sun W, Cai L, Xu C, Cui S.

Cell Physiol Biochem. 2014;33(1):78-87. doi: 10.1159/000356651. Epub 2014 Jan 17.

18.

Dominant negative effects of the AML1/ETO fusion oncoprotein.

Fenske TS, Pengue G, Graubert TA.

Cell Cycle. 2005 Jan;4(1):33-6. Epub 2005 Jan 19.

PMID:
15611635
19.

AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression.

Yeh JR, Munson KM, Chao YL, Peterson QP, Macrae CA, Peterson RT.

Development. 2008 Jan;135(2):401-10.

20.

Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.

Maiques-Diaz A, Chou FS, Wunderlich M, Gómez-López G, Jacinto FV, Rodriguez-Perales S, Larrayoz MJ, Calasanz MJ, Mulloy JC, Cigudosa JC, Alvarez S.

Leukemia. 2012 Jun;26(6):1329-37. doi: 10.1038/leu.2011.376. Epub 2012 Jan 13.

PMID:
22289984

Supplemental Content

Support Center